Rhythm Pharmaceuticals offers ways to help cover the cost of your medicine. These include:
Co-pay assistance program
This program may help cover out-of-pocket costs associated with IMCIVREE, up to $8,550 per year. To be eligible, you must have a qualifying diagnosis, a commercial insurance policy (coverage from a private company), and a prescription for IMCIVREE.
Patient assistance program
This program can help individuals with a qualifying diagnosis who are uninsured, who have temporarily lost insurance coverage, or whose insurance doesn’t cover IMCIVREE. Speak to a Care Partner to find out about eligibility and the enrollment process.
IMCIVREE is a treatment for obesity due to POMC, PCSK1, or LEPR deficiency confirmed through a genetic test. The test must show that the change, or variant, is considered pathogenic, likely pathogenic, or uncertain. IMCIVREE should not be used by someone with obesity due to suspected POMC, PCSK1, or LEPR deficiency not confirmed by genetic testing (benign or likely benign result) or someone with another type of obesity not related to POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic conditions and general obesity. It’s always best to talk to your healthcare provider to determine if a treatment is right for you.
Each individual is different, and results can vary from person to person. In clinical studies of IMCIVREE:
- 80% of people (8 out of 10) with obesity due to POMC or PCSK1 deficiency lost at least 10% of their body weight at 1 year; people with obesity due to POMC or PCSK1 deficiency had a 23.1% average reduction in weight from baseline after 1 year.
- 46% of people (5 out of 11) with obesity due to LEPR deficiency lost at least 10% of their body weight at 1 year; people with obesity due to LEPR deficiency had a 9.7% average reduction in weight from baseline after 1 year.
When treatment was stopped, weight increased. When the withdrawal period ended and treatment was restarted, weight loss continued. You can find more information on IMCIVREE clinical studies here. To determine what may be reasonable for you to expect from treatment, speak to your healthcare provider.
IMCIVREE may cause serious side effects, including:
- Male and female sexual function problems. IMCIVREE can cause an erection that happens without any sexual activity in males (spontaneous penile erection) and unwanted sexual reactions (changes in sexual arousal that happen without any sexual activity) in females. If you have an erection lasting longer than 4 hours, get emergency medical help right away.
- Depression and suicidal thoughts or actions. You or a caregiver should call your healthcare provider right away if you have any new or worsening symptoms of depression.
- Increased skin pigmentation and darkening of skin lesions (moles or nevi) you already have. These changes happen due to how IMCIVREE works in the body and will go away when you stop using IMCIVREE. You should have a full body skin exam before starting and during treatment with IMCIVREE to check for skin changes.
- Benzyl alcohol toxicity. Benzyl alcohol is a preservative in IMCIVREE. Benzyl alcohol can cause serious side effects, including death, in premature and low-birth weight infants, who have received medicines that contain benzyl alcohol. IMCIVREE should not be used in premature and low-birth weight infants.
The most common side effects were injection site reactions, darkening of the skin, nausea, headache, diarrhea, abdominal pain, back pain, fatigue, vomiting, depression, upper respiratory tract infection, and erections that happen without any sexual activity in males. These are not all the possible side effects of IMCIVREE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Rhythm Pharmaceuticals at 1-833-789-6337.
It's best to reach out to your current healthcare provider for more information. In phase 3 clinical studies evaluating IMCIVREE for the treatment of obesity due to POMC, PCSK1, and LEPR deficiency, nausea was reported by 56% of people taking IMCIVREE, and vomiting was reported by 30% of people taking IMCIVREE. Responses vary, but these two effects were most often reported in the first month after starting treatment, and were reported less frequently over time.
IMCIVREE must be taken daily to be effective. In clinical trials, when IMCIVREE was stopped, individuals experienced weight gain. When the withdrawal period ended and treatment was restarted, weight loss continued. Speak to your healthcare provider to determine the best treatment plan for you.
Insurance coverage varies from plan to plan. We invite you to contact IMCIVREE GPS at 1-844-YOUR-GPS (1-844-968-7477). Our team members would be happy to help you look into options and plan next steps.
The first place to turn is always your healthcare provider, who can determine the right treatment for you. IMCIVREE GPS may also be able to help with questions about taking IMCIVREE, insurance coverage, financial support programs, and ongoing support. Contact IMCIVREE GPS at 1-844-YOUR-GPS (1-844-968-7477).
A guide to treatment
This brochure provides helpful information about what to expect on treatment.
A guide to injecting
This guide outlines the steps you’ll need to take to understand your dose, safely inject IMCIVREE, and find support when needed.
Injection training video
This video demonstrates how to inject and store your medicine.